Core Insights - Jefferies initiated coverage on Gilead Sciences with a Buy rating and a price target of $180, while assigning a Hold rating to Amgen with a target of $350, reflecting differing views on their respective valuations and growth potential [1][2] - JPMorgan maintained an Overweight rating on Oric Pharmaceuticals, emphasizing the unjustified nature of its recent stock pullback due to competitor news [1] Gilead Sciences (GILD) - Jefferies views Gilead as well-positioned due to a clean intellectual property runway until 2036, high operating margins, and the ability to invest in its pipeline while returning capital to shareholders [1] - Gilead reported Q4 2025 revenue of $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, up 2% year-over-year [1] - The company's flagship HIV therapy, Biktarvy, generated $3.97 billion in Q4, while Descovy surged 33% to $819 million [1] Amgen Inc. (AMGN) - Jefferies acknowledged Amgen's strong execution but concluded that a 35% stock run-up has left limited near-term upside, with the stock currently trading above the $350 target [1][2] - Amgen's Q4 revenue was $9.87 billion, surpassing the estimate of $9.66 billion, with a notable growth in Repatha at +44% to $870 million, while Enbrel saw a decline of 48% to $532 million [1] Oric Pharmaceuticals Inc. (ORIC) - JPMorgan's reaffirmation of Oric's Overweight rating comes after a 16.07% drop in shares due to competitor news, which the firm believes does not reflect the fundamentals of Oric's pipeline [1] - Oric's lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer, with a Phase 3 trial initiation expected in H1 2026 [1] - The company holds $392.3 million in cash, projecting a funding runway into the second half of 2028, with shares up 42.42% year-to-date despite recent pullbacks [1]

Core Insights - Jefferies has initiated coverage on Gilead Sciences with a Buy rating and a $180 price target, while assigning a Hold rating to Amgen with a $350 price target, indicating a nuanced view on the biopharma sector [3][5][10] Gilead Sciences - Gilead is positioned as one of the best large-cap biotechs, benefiting from a clean intellectual-property runway until 2036, high operating margins, and overlapping franchises [2][4] - Q4 2025 revenue was $7.93 billion, exceeding the consensus estimate of $7.85 billion, with a full-year revenue of $29.4 billion, reflecting a 2% year-over-year increase [7] - Non-GAAP EPS for Q4 was $1.86, slightly above the estimate of $1.85, and full-year non-GAAP EPS rose significantly to $8.15 from $4.62 in 2024 [7] - The HIV therapy Biktarvy generated $3.97 billion in Q4, up 5%, while Descovy surged 33% to $819 million, with the newly launched Yeztugo expected to be a commercial catalyst [7] - Gilead's stock is currently trading at $146.63, up 19.46% year-to-date, with a forward P/E of 16x reflecting guidance of non-GAAP EPS of $8.45 to $8.85 in 2026 [5][11] Amgen Inc. - Amgen reported Q4 revenue of $9.87 billion, surpassing the estimate of $9.66 billion, with non-GAAP EPS of $5.29, well above the $4.83 estimate [8] - The growth driver was Repatha, which increased by 44% to $870 million, while Enbrel saw a significant decline of 48% to $532 million [8] - Amgen shares are currently trading at $376.97, reflecting a 15.96% year-to-date increase, but are above Jefferies' $350 target, indicating limited near-term upside [5][12] Oric Pharmaceuticals - Oric is a clinical-stage oncology company with no product revenue, but its lead asset, rinzimetostat, has shown a 55% PSA50 response rate in metastatic castration-resistant prostate cancer [9] - The company holds $392.3 million in cash, providing a funding runway into the second half of 2028, despite a recent 16.07% drop in shares due to competitor news [6][9] - The consensus analyst target for Oric is $21.23, while its current price is $11.65, indicating potential upside [9] Analyst Perspectives - Gilead's long IP runway and diversified revenue base, along with a 2.2% dividend yield, make it attractive to income-oriented investors [13] - Amgen's stock has largely priced in strong execution, with risks from biosimilar competition and an unproven obesity pipeline [12][14] - Oric's binary risk nature is highlighted, with significant implications for stock performance based on upcoming clinical data readouts [15]

Summary of Oric Pharmaceuticals FY Conference Call Company Overview - **Company**: Oric Pharmaceuticals (NasdaqGS:ORIC) - **Industry**: Clinical stage oncology - **Focus Areas**: Prostate cancer, lung cancer, and breast cancer [2][3] Key Programs 1. **Rinzimetostat (ORIC-944)**: - Allosteric PRC2 inhibitor targeting prostate cancer in combination with AR inhibitors (apalutamide and darolutamide) [2][3] - Phase III study expected to start in the first half of 2026 [3][4] - Early clinical data shows promising PSA response rates and favorable safety profile compared to Pfizer's data [5][17] 2. **Enosertinib**: - EGFR inhibitor with high potency on exon 20 and PAK mutations [3][43] - Demonstrated 100% overall response rate in patients with measurable disease, including those with untreated brain metastases [43] Market Opportunity - **Prostate Cancer**: - Large patient population with significant unmet needs; over $11 billion in sales for ARPi inhibitors last year [23][24] - Potential to reverse resistance to current therapies and extend treatment duration [24][25] - **Lung Cancer**: - High prevalence of CNS metastases in lung cancer patients, making CNS activity a critical differentiator for enosertinib [43][44] Competitive Landscape - **Rinzimetostat vs. Mevrometostat**: - Rinzimetostat is positioned as a potentially best-in-class PRC2 inhibitor with better drug properties, including solubility and half-life [11][12] - Early data suggests lower rates of gastrointestinal and hematological toxicities compared to competitors [17] - **Enosertinib's Differentiation**: - Focus on CNS activity and less off-target toxicities compared to competitors [43][44] Upcoming Milestones - **Rinzimetostat**: - Q1 update with data from 20-25 patients expected, focusing on PSA50, PSA90, safety, and tolerability [38][39] - Phase III study initiation in the first half of 2026 [3][38] - **Enosertinib**: - Continued evaluation of monotherapy and combination strategies, with updates expected in the second half of 2026 [48][49] Investor Considerations - The stock's performance is closely tied to the outcomes of the MEVPRO-1 study and the company's own data releases [53][56] - Rinzimetostat is viewed as a potential blockbuster if it demonstrates differentiation in safety and efficacy [58] Conclusion Oric Pharmaceuticals is strategically positioned in the oncology space with promising drug candidates targeting significant unmet needs in prostate and lung cancers. The upcoming data releases and competitive positioning will be critical for investor confidence and stock performance moving forward.

Core Insights - ORIC Pharmaceuticals reported promising Phase 1b data for rinzimetostat and enozertinib, indicating potential best-in-class efficacy and safety in treating metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) respectively [1][2][3] Financial Highlights - The company raised $264 million from healthcare specialist funds, providing a cash runway into the second half of 2028 [1] - As of December 31, 2025, cash, cash equivalents, and investments totaled $392.3 million, with an additional $20 million raised post-quarter, resulting in pro forma cash and investments of $412.3 million [5][6] Clinical Development Updates - Rinzimetostat demonstrated significant PSA responses and ctDNA reductions in mCRPC patients, with 55% achieving a PSA50 response and 20% achieving a PSA90 response [4] - Enozertinib showed competitive systemic and intracranial activity in NSCLC patients, with a 67% overall response rate (ORR) in EGFR exon 20 mutations and 80% ORR in EGFR PACC mutations [7] - The company plans to initiate a global Phase 3 registrational trial for rinzimetostat in mCRPC in the first half of 2026 and expects multiple clinical data readouts in 2026 [5][6] Research and Development Expenses - R&D expenses for Q4 2025 were $25.9 million, down from $32.0 million in Q4 2024, and for the full year, R&D expenses were $109.8 million compared to $114.1 million in 2024 [6][13] - General and administrative expenses increased to $8.7 million for Q4 2025 from $7.6 million in Q4 2024, reflecting higher personnel costs and professional services [6][13] Upcoming Milestones - Anticipated milestones include combination dose optimization data for rinzimetostat in Q1 2026 and monotherapy data for enozertinib in the second half of 2026 [5][6]

Core Viewpoint - ORIC Pharmaceuticals is focused on overcoming resistance in cancer, with a mission to develop innovative therapies for oncology patients [3]. Company Overview - ORIC has assembled a team of experienced drug hunters and developers who have previously worked at leading oncology companies, contributing to the development of successful and commercialized products [3]. Pipeline Assets - The company has two late-stage pipeline assets: rinzimetostat, targeting prostate cancer, and enozertinib, aimed at lung cancer [4]. - Significant data on both drugs has been presented in previous years, particularly in 2025, with more data expected to be shared in the current year [4].

Core Insights - ORIC Pharmaceuticals announced promising Phase 1b data for rinzimetostat and enozertinib, indicating potential best-in-class efficacy and safety in treating metastatic castration-resistant prostate cancer (mCRPC) and non-small cell lung cancer (NSCLC) respectively [1][2][4] - The company raised $244 million from healthcare specialist funds, providing a cash runway into the second half of 2028, which supports ongoing clinical trials and potential commercialization efforts [1][8] - Multiple clinical data readouts for rinzimetostat and enozertinib are expected in 2026, ahead of the initiation of several registrational trials [1][2] Rinzimetostat Highlights - Rinzimetostat is a potent and selective allosteric inhibitor of PRC2, showing significant PSA responses and ctDNA reductions in mCRPC patients [3][5] - In combination with darolutamide and apalutamide, 55% of patients achieved a PSA50 response, and 20% achieved a PSA90 response, with rapid ctDNA responses observed [5] - The safety profile of rinzimetostat in combination regimens is favorable, with most treatment-related adverse events being Grade 1 or 2 [5] Enozertinib Highlights - Enozertinib is a brain-penetrant inhibitor targeting EGFR exon 20 and EGFR PACC mutations, demonstrating competitive systemic and intracranial activity in NSCLC patients [4][11] - The Phase 1b trial reported a 67% overall response rate (ORR) in EGFR exon 20 and an 80% ORR in EGFR PACC, with 100% intracranial ORR in patients with measurable CNS disease [11] - A clinical trial collaboration with Johnson & Johnson was announced to evaluate enozertinib in combination with amivantamab for first-line treatment of NSCLC patients [11] Financial Position - As of September 30, 2025, ORIC's cash, cash equivalents, and investments totaled $413 million, expected to fund operations into the second half of 2028 [8] - The company has strengthened its cash position through a private placement and an at-the-market program throughout 2025 [11] Upcoming Milestones - For rinzimetostat, the company plans to report combination dose optimization data in Q1 2026 and initiate the first global Phase 3 trial in mCRPC in the first half of 2026 [11] - For enozertinib, monotherapy data for EGFR exon 20 and PACC is anticipated in the second half of 2026 [11]